#Sakar healthcare cmp around 148 , oncology expansion is going on ( drugs and API ) .
-The company’s product profile is diversified and
comprises liquid injectables, tablets/capsules, oral liquid syrups, dry powder injections and syrups, and lyophilised
injectables.
-The product portfolio remains diversified with approximately 300 product registrations
comprises liquid injectables, tablets/capsules, oral liquid syrups, dry powder injections and syrups, and lyophilised
injectables.
-The product portfolio remains diversified with approximately 300 product registrations
Business model
1-The company manufactures and markets its product through own distribution channels
across Africa, Latin America, Asia and South East Asia and CIS countries.
•.
1-The company manufactures and markets its product through own distribution channels
across Africa, Latin America, Asia and South East Asia and CIS countries.
•.
Company has received necessary approvals from national drug authority of Kenya,
Uganda, Yemen, Ethiopia, Congo, Ghana, Zimbabwe, Nigeria, Malawi, Cambodia,
Philippines, Vietnam, Peru & Cote-D’lvoire, to export and market the products in those
countries.
Uganda, Yemen, Ethiopia, Congo, Ghana, Zimbabwe, Nigeria, Malawi, Cambodia,
Philippines, Vietnam, Peru & Cote-D’lvoire, to export and market the products in those
countries.
2-• CMO Buainess- The company is manufacturing Pharmaceutical products on contracts basis for reputed
clients.
• Some of the leading pharmaceutical brands in India are manufactured at Sakar
clients.
• Some of the leading pharmaceutical brands in India are manufactured at Sakar
Manufacturing facility
-located at Changodar near Ahmedabad, Gujarat; the unit is ISO 9001:2008, WHO-GMP and EU-GMP certified (liquid and lyophilised injectables units).
-located at Changodar near Ahmedabad, Gujarat; the unit is ISO 9001:2008, WHO-GMP and EU-GMP certified (liquid and lyophilised injectables units).
- company has obtained European Union good manufacturing practice (EU-GMP) certification for its existing liquid and lyophilised injectables units, in accordance with the
European Medicines Agency (EMA) standards
European Medicines Agency (EMA) standards
Clients- (2018 information )
capex-( Capex for oncology drugs)
. The commercial operations for the ongoing capex
formulations and the API units are expected to commence from Q2FY2022, while the liquid and lyophilized unit is expected to begin its commercial operations from Q2FY2023
. The commercial operations for the ongoing capex
formulations and the API units are expected to commence from Q2FY2022, while the liquid and lyophilized unit is expected to begin its commercial operations from Q2FY2023
-Swiss based HBM Healthcare
Investments; a leading global healthcare private equity recently invested Rs 14.85 crore in Sakar Healthcare
through its wing COBRA.
Investments; a leading global healthcare private equity recently invested Rs 14.85 crore in Sakar Healthcare
through its wing COBRA.
Risk is -
- delay in expansion and debt trap
- increasing competition
- not much information is available about promoters quality
- promoters are Having another company Bisil plast which was a penny stock and now not traded
So invest carefully.
- delay in expansion and debt trap
- increasing competition
- not much information is available about promoters quality
- promoters are Having another company Bisil plast which was a penny stock and now not traded
So invest carefully.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
